Pfizer, Genentech Target Roxane Over Generic Cancer Drug

Law360, New York (December 7, 2012, 5:39 PM EST) -- Pfizer Inc., Genentech Inc. and Astellas Pharma Inc. unit OSI Pharmaceuticals LLC on Friday sued Roxane Laboratories Inc. in Delaware federal court over the generic-drug maker's bid for approval to market a version of the cancer treatment Tarceva for the second time this year.

OSI, Pfizer and Genentech claim that Roxane, a subsidiary of drug giant Boehringer Ingelheim Corp., violated three patents for the nonsmall-cell lung cancer drug when it filed its abbreviated new drug application with the U.S. Food and Drug Administration earlier this year....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.